Effects of Predation on Two Species of Stream-Dwelling Crayfish (Orconectes marchandi and Cambarus hubbsi) in Pool and Riffle Microhabitats

Community structure may be governed by many abiotic and biotic factors. Of the biotic factors, predation is often considered to be critical in structuring freshwater stream communities. In the Warm Fork of the Spring River, the crayfish Cambarus hubbsi is found mainly in riffles, whereas the crayfish Orconectes marchandi is found in high numbers in pools. We hypothesized that predation, mainly by fish, is a factor causing this segregation. Higher predation rates for C. hubbsi than 0. marchandi in the pools and higher predation rates for 0. marchandi than C. hubbsi in the riffles were expected. A transplant tethering experiment was conducted to test whether predation influences habitat selection. Substrate, water depth, and current velocity were also taken into account. In the pool, predation rates were significantly greater on C. hubbsi than 0. marchandi, but predation rates were equal for the two species in the riffle. This suggests that predation is a factor in keeping C. hubbsi out of pools, but is not a factor in keeping 0. marchandi out of riffles. Also, significantly greater predation rates overall were found in the pool than in the riffle. The pool was significantly deeper and had lower substrate diversity than the riffle. These findings suggest that predators are important in affecting crayfish habitat use; differential predation rates occur between habitats and greater predation rates occur in pools than in riffles

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

Background: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown. Design and methods: The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure trial (DAPA‐HF) is an international, multicentre, parallel group, randomized, double‐blind, study in patients with chronic heart failure, evaluating the effect of dapagliflozin 10 mg, compared with placebo, given once daily, in addition to standard care, on the primary composite outcome of a worsening heart failure event (hospitalization or equivalent event, i.e. an urgent heart failure visit) or cardiovascular death. Patients with and without diabetes are eligible and must have a left ventricular ejection fraction ≤ 40%, a moderately elevated N‐terminal pro B‐type natriuretic peptide level, and an estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2. The trial is event‐driven, with a target of 844 primary outcomes. Secondary outcomes include the composite of total heart failure hospitalizations (including repeat episodes), and cardiovascular death and patient‐reported outcomes. A total of 4744 patients have been randomized. Conclusions: DAPA‐HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in a broad spectrum of patients with heart failure and reduced ejection fraction